Advanced Medical Isotope (OTCMKTS:RDGL) & Oxford Square Capital (NASDAQ:OXSQ) Head to Head Review

Advanced Medical Isotope (OTCMKTS:RDGL) and Oxford Square Capital (NASDAQ:OXSQ) are both small-cap finance companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, valuation, dividends and earnings.

Analyst Ratings

This is a breakdown of recent ratings for Advanced Medical Isotope and Oxford Square Capital, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Advanced Medical Isotope	0	0	0	0	0.00
Oxford Square Capital	1	0	0	0	1.00

Profitability

This table compares Advanced Medical Isotope and Oxford Square Capital’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Advanced Medical Isotope	-6,401.92%	N/A	-139.36%
Oxford Square Capital	-3.35%	15.19%	8.11%

Institutional & Insider Ownership

6.4% of Oxford Square Capital shares are owned by institutional investors. 18.5% of Advanced Medical Isotope shares are owned by company insiders. Comparatively, 8.6% of Oxford Square Capital shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Risk & Volatility

Advanced Medical Isotope has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500.Comparatively, Oxford Square Capital has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500.

Earnings and Valuation

This table compares Advanced Medical Isotope and Oxford Square Capital”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Advanced Medical Isotope	$30,000.00	1,094.23	-$2.91 million	N/A	N/A
Oxford Square Capital	$1.81 million	83.11	$5.88 million	($0.04)	-46.13

Oxford Square Capital has higher revenue and earnings than Advanced Medical Isotope.

Summary

Oxford Square Capital beats Advanced Medical Isotope on 7 of the 10 factors compared between the two stocks.

About Advanced Medical Isotope

Vivos Inc., a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors in the United States. It develops yttrium-90 based RadioGel device, an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc. in December 2017. Vivos Inc. was incorporated in 1994 and is headquartered in Richland, Washington.

About Oxford Square Capital

Oxford Square Capital Corp. is a business development company, operates as a closed-end, non-diversified management investment company. It is a private equity and mezzanine firm. The firm invests in both public and private companies. It invests in secured and unsecured senior debt, subordinated debt, junior subordinated debt, preferred stock, common stock and syndicated bank loans. The firm primarily invests in debt and/or equity securities of technology-related companies that operate in the computer software, Internet, information technology infrastructure and services, media, telecommunications and telecommunications equipment, semiconductors, hardware, technology-enabled services, semiconductor capital equipment, medical device technology, diversified technology, and networking systems sectors. It concentrates its investments in companies having annual revenues of less than $200 million and a market capitalization or enterprise value of less than $300 million. The firm invests between $5 million and $30 million per transaction. It seeks to exit its investments within 7 years. It serves as the investment adviser to TICC. Oxford Square Capital Corp., formerly known as TICC Capital Corp., was founded in 2003 and is headquartered in Greenwich, Connecticut.